Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis

被引:5
|
作者
Meisel, Andreas [1 ,5 ]
Sacca, Francesco [2 ]
Spillane, Jennifer [3 ]
Vissing, John [4 ]
机构
[1] Charite Univ Med Berlin, Neurosci Clin Res Ctr, Dept Neurol Expt Neurol, Berlin, Germany
[2] Federico II Univ Naples, GENESIS Dept, Naples, Italy
[3] Natl Hosp Neurol & Neurosurg, UCLH NHS Fdn Trust, London, England
[4] Copenhagen Univ Hosp, Rigshosp, Rigshospitalet, Copenhagen, Denmark
[5] Charite Univ Med Berlin, Dept Neurol Expt Neurol, Charite Pl 1, D-10117 Berlin, Germany
关键词
ADL; consensus; Delphi study; generalised; myasthenia gravis; patient care; QoL; QUALITY-OF-LIFE; DOUBLE-BLIND; EFFICACY; FATIGUE; VALIDATION; ECULIZUMAB; SYMPTOM; SAFETY; IMPACT;
D O I
10.1111/ene.16280
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundRegular and consistent disease assessment could provide a clearer picture of burden in generalised myasthenia gravis (gMG) and improve patient care; however, the use of assessment tools in practice lacks standardisation. This modified Delphi approach was taken to review current evidence on assessment tool use in gMG and develop expert-derived consensus recommendations for good practice.MethodsA European expert panel of 15 experienced gMG neurologists contributed to development of this consensus, four of whom formed a lead Sub-committee. The PICO (Population, Intervention, Control, Outcomes) framework was used to define six clinical questions on gMG assessment tools, a systematic literature review was conducted, and evidence-based statements were developed. According to a modified Delphi voting process, consensus was reached when >= 70% of the experts rated agreement with a statement as >= 8 on a scale of 1-10.ResultsEighteen expert- and evidence-based consensus statements based on six themes were developed. Key recommendations include: consistent use of the Myasthenia Gravis Activities of Daily Living score (MG-ADL) across clinical settings, followed by a simple question (e.g., Patient Acceptable Symptom State [PASS]) or scale to determine patient satisfaction in clinical practice; use of a Quantitative Myasthenia Gravis [QMG] or quality of life [QoL] assessment when the MG-ADL indicates disease worsening; and consideration of symptom state to determine the timing and frequency of recommended assessments. Expert panel consensus was reached on all 18 statements after two voting rounds.ConclusionsThis process provided evidence- and expert consensus-based recommendations for the use of objective and subjective assessment tools across gMG research and care to improve management and outcomes for patients.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Iranian Consensus Recommendations for Treatment of Myasthenia Gravis
    Nafissi, Shahriar
    Okhovat, Ali Asghar
    Sinaei, Farnaz
    Ansari, Behnaz
    Ayramloo, Hormoz
    Basiri, Keyvan
    Boostani, Reza
    Ashtiani, Bahram Haghi
    Sarraf, Payam
    Fatehi, Farzad
    ARCHIVES OF IRANIAN MEDICINE, 2022, 25 (01) : 37 - 49
  • [2] STATE ANXIETY ASSESSMENT IN PATIENTS WITH MYASTHENIA GRAVIS
    Kalbus, O., I
    WORLD OF MEDICINE AND BIOLOGY, 2021, 76 (02): : 48 - 52
  • [3] The impact of diagnosis delay on European patients with generalised myasthenia gravis
    Cortes-Vicente, Elena
    Borsi, Andras J.
    Gary, Charlotte
    Noel, Wim G. J.
    Lee, Jennifer M. S.
    Karmous, Wisam
    Zhang, Qiaoyi
    Gandhi, Kavita H.
    Batista, Alberto E.
    Decourcy, Jonathan J.
    Barlow, Sophie G.
    Birija, Shiva L.
    Gibson, Gregor A.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (09): : 2254 - 2267
  • [4] Impact of Thymectomy on Crisis Incidence and Quality of Life amongst Generalised Myasthenia Gravis Patients
    Kanikannan, Meena A.
    Reddy, Pavan K.
    Mathukumalli, Neeharika L.
    Yareeda, Sireesha
    Borgohain, Rupam
    NEUROLOGY INDIA, 2022, 70 (06) : 2427 - 2431
  • [5] Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis
    de la Borderie, Guillemette
    Chimits, Damien
    Boroojerdi, Babak
    Brock, Melissa
    Duda, Petra W.
    Grimson, Fiona
    Mahoney, Paul
    Strimenopoulou, Foteini
    Cutter, Gary
    Aban, Inmaculada
    Brauner, Susanna
    Petersson, Malin
    Howard Jr, James F.
    Bennett, Nathan
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [6] Assessment of esophageal function in patients with myasthenia gravis
    Linke, R
    Witt, TN
    Tatsch, K
    JOURNAL OF NEUROLOGY, 2003, 250 (05) : 601 - 606
  • [7] Office-based respiratory assessment in patients with generalized myasthenia gravis
    Alcantara, Monica
    Barnett-Tapia, Carolina
    Bril, Vera
    Mannan, Shabber
    Shabanpour, Jafar
    Riaz, Sarah
    Ng, Eduardo
    Ryan, Clodagh
    Katzberg, Hans
    NEUROMUSCULAR DISORDERS, 2024, 40 : 1 - 6
  • [8] Videofluoroscopic assessment of swallowing function in patients with myasthenia gravis
    Higo, R
    Nito, T
    Tayama, N
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 231 (1-2) : 45 - 48
  • [9] Is the treatment of myasthenia gravis improving? Why not ask our patients?
    Piehl, Fredrik
    Wolfe, Gil I.
    NEUROLOGY, 2020, 95 (12) : 509 - 510
  • [10] Evaluation of a scale of patient-reported outcomes for the assessment of myasthenia gravis patients in China
    Feng-bin Liu
    Xin-lin Chen
    Li Guo
    Xiao-bin Liu
    Chinese Journal of Integrative Medicine, 2012, 18 : 737 - 745